{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:38:39Z","timestamp":1790638719873,"version":"4.1.0"},"reference-count":82,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Hypophosphatemia is a rare ion disorder in children, but it carries the risk of serious clinical sequelae in tissues and organs with high energy requirements, such as bone tissue. This article discusses the metabolism of phosphate in the body, the clinical manifestations of hypophosphatemia, and the diagnostic tests necessary in patients with this disorder. Extra-renal causes are analyzed, and renal forms of hypophosphatemia are discussed in detail. Renal hypophosphatemia, depending on the mechanism, is divided into PTH-dependent (e.g., primary hyperparathyroidism), FGF23-dependent (e.g., X-linked hypophosphatemia), and intrinsic renal hypophosphatemia (e.g., Fanconi syndrome). The treatment of hypophosphatemia involves compensating for phosphate deficiency, often simultaneously with the supply of an active form of vitamin D. Always seek causal treatment, such as parathyroidectomy in primary hyperparathyroidism. In the FGF-23-dependent forms of X-linked hypophosphatemia and tumor-induced osteomalacia, burosumab has proven to be an effective and safe drug. Conclusions: a child with hypophosphatemia requires a multidisciplinary approach and determination of the mechanism of phosphate deficiency in the body.<\/jats:p>","DOI":"10.3390\/biom15091321","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:27:33Z","timestamp":1757953653000},"page":"1321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Approach to a Child with Hypophosphatemia"],"prefix":"10.3390","volume":"15","author":[{"given":"Agnieszka","family":"Antonowicz","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-8375","authenticated-orcid":false,"given":"Patryk","family":"Lipi\u0144ski","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, Maria Sk\u0142odowska-Curie Medical Academy, 00-136 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Popow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-8255","authenticated-orcid":false,"given":"Piotr","family":"Skrzypczyk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00467-024-06395-5","article-title":"The role of fibroblast growth factor 23 in regulation of phosphate balance","volume":"39","author":"Wilson","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ndt\/gfad188","article-title":"The basics of phosphate metabolism","volume":"39","author":"Wagner","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101851","DOI":"10.1016\/j.beem.2023.101851","article-title":"The pathophysiology of hypophosphatemia","volume":"38","author":"Ito","year":"2024","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/1535370219831220","article-title":"Intestinal phosphate absorption: The paracellular pathway predominates?","volume":"244","author":"Saurette","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1573396319666221221121350","article-title":"Phosphate Homeostasis and Disorders of Phosphate Metabolism","volume":"20","author":"Perumal","year":"2024","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.ajkd.2023.04.017","article-title":"Calcium and Phosphate Disorders: Core Curriculum 2024","volume":"83","author":"Murray","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.beem.2018.06.004","article-title":"Phosphate homeostasis disorders","volume":"32","author":"Christov","year":"2018","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4s3","DOI":"10.1016\/S0929-693X(24)00151-9","article-title":"Biology of bone mineralization and ectopic calcifications: The same actors for different plays","volume":"31","author":"Magne","year":"2024","journal-title":"Arch. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00223-020-00686-3","article-title":"Phosphate Metabolism in Health and Disease","volume":"108","author":"Peacock","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00467-019-04290-y","article-title":"Mineralized tissues in hypophosphatemic rickets","volume":"35","author":"Robinson","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(24)01305-9","article-title":"X-linked hypophosphataemia","volume":"404","author":"Briot","year":"2024","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/j.2040-4603.2016.tb00690.x","article-title":"PTH and Vitamin D","volume":"6","author":"Khundmiri","year":"2016","journal-title":"Compr. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"F1232","DOI":"10.1152\/ajprenal.00025.2007","article-title":"Mechanisms underlying the long-term regulation of NHE3 by parathyroid hormone","volume":"294","author":"Bezerra","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.micpath.2019.03.041","article-title":"The lung microbiome, vitamin D, and the tuberculous granuloma: A balance triangle","volume":"131","author":"Balcells","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","article-title":"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain","volume":"277","author":"Yamashita","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"(2000). Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet., 26, 345\u2013348.","DOI":"10.1038\/81664"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/1873-3468.13494","article-title":"Regulation of fibroblast growth factor 23 (FGF23) in health and disease","volume":"593","author":"Stournaras","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_18","first-page":"17","article-title":"FGF23 and Associated Disorders of Phosphate Wasting","volume":"17","author":"Gohil","year":"2019","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/JME-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J. Mol. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","article-title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting","volume":"103s","author":"Bacchetta","year":"2020","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1006\/bbrc.1997.8019","article-title":"Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein","volume":"242","author":"Matsumura","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00467-012-2347-x","article-title":"Phosphate is a vascular toxin","volume":"28","author":"Shroff","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital Conditions of Hypophosphatemia in Children","volume":"108","author":"Imel","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-021-05328-w","article-title":"Rickets guidance: Part I-diagnostic workup","volume":"37","author":"Haffner","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/clinem\/dgad597","article-title":"LMS-Based Pediatric Reference Values for Parameters of Phosphate Homeostasis in the HARP Cohort","volume":"109","author":"Pott","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10408363.2017.1379945","article-title":"The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper","volume":"54","author":"Adeli","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_28","unstructured":"Kliegman, R.M., and Geme, J.W.S. (2024). Nelson Textbook of Pediatrics, Elsevier. [22nd ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/jbmr.4702","article-title":"Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia","volume":"37","author":"Hartley","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J. Trop. Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Laurent, M.R., De Schepper, J., Trouet, D., Godefroid, N., Boros, E., Heinrichs, C., Bravenboer, B., Velkeniers, B., Lammens, J., and Harvengt, P. (2021). Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.641543"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Mughal","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000245640","article-title":"Phosphate elimination in modalities of hemodialysis and peritoneal dialysis","volume":"29","author":"Kuhlmann","year":"2010","journal-title":"Blood Purif"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhou, X., He, J., Zhu, D., Yao, Z., Peng, D., and Zhang, X. (2023). Relationship between serum phosphate and mortality in critically ill children receiving continuous renal replacement therapy. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1129156"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5049\/EBP.2022.20.2.64","article-title":"Management for Electrolytes Disturbances during Continuous Renal Replacement Therapy","volume":"20","author":"Baeg","year":"2022","journal-title":"Electrolytes Blood Press."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/sdi.12677","article-title":"Prevention of hypophosphatemia during continuous renal replacement therapy-An overlooked problem","volume":"31","author":"Heung","year":"2018","journal-title":"Semin. Dial."},{"key":"ref_39","unstructured":"Cartwright, C., and Anastasopoulou, C. (2025). Hungry Bone Syndrome. StatPearls, StatPearls Publishing LLC."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MNH.0000000000000327","article-title":"Hungry bone syndrome","volume":"26","author":"Jain","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s00247-021-05050-7","article-title":"Pediatric hyperparathyroidism: Review and imaging update","volume":"51","author":"Khalatbari","year":"2021","journal-title":"Pediatr. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/jbmr.3296","article-title":"Hypercalcemic Disorders in Children","volume":"32","author":"Stokes","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Levine, M.A. (2020). Diagnosis and Management of Vitamin D Dependent Rickets. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.00315"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1681\/ASN.2014101025","article-title":"Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia","volume":"27","author":"Schlingmann","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/ndt\/gfaa178","article-title":"Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations","volume":"36","author":"Janiec","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.kint.2024.02.006","article-title":"Hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a complex disorder in need of precision medicine","volume":"105","author":"Schinke","year":"2024","journal-title":"Kidney Int."},{"key":"ref_48","first-page":"1580","article-title":"Clinical Spectrum of Hereditary Hypophosphatemic Rickets With Hypercalciuria (HHRH)","volume":"37","author":"Heider","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00424-018-2184-2","article-title":"Hereditary hypophosphatemic rickets with hypercalciuria: Pathophysiology, clinical presentation, diagnosis and therapy","volume":"471","author":"Bergwitz","year":"2019","journal-title":"Pflug. Arch."},{"key":"ref_50","first-page":"e81236","article-title":"Managing Ifosfamide-Induced Arginine Vasopressin Resistance: Diagnostic and Treatment Strategies","volume":"17","author":"Williams","year":"2025","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000527931","article-title":"Severe Hypophosphatemia as the Initial Presentation of Renal Fanconi\u2019s Syndrome and Distal Renal Tubular Acidosis Related to Zoledronic Acid: A Case Report and Literature Review","volume":"48","author":"Wu","year":"2023","journal-title":"Kidney Blood Press. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2021.12.015","article-title":"Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer","volume":"80","author":"Mount","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"392","DOI":"10.12659\/AJCR.907503","article-title":"Sj\u00f6gren\u2019s Syndrome Associated with Fanconi\u2019s Syndrome and Osteomalacia","volume":"19","author":"Gutierrez","year":"2018","journal-title":"Am. J. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrneph.2015.174","article-title":"Renal involvement in primary Sj\u00f6gren syndrome","volume":"12","author":"Mariette","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1006\/bbrc.2001.5084","article-title":"FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate","volume":"284","author":"Bowe","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.beem.2023.101834","article-title":"Tumor-induced osteomalacia: An overview","volume":"38","author":"Jadhav","year":"2024","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1210\/endrev\/bnac026","article-title":"Tumor-induced Osteomalacia: A Comprehensive Review","volume":"44","author":"Minisola","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-Induced Osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","article-title":"Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy","volume":"75","author":"Lim","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s00198-016-3702-8","article-title":"Cutaneous skeletal hypophosphatemia syndrome: Clinical spectrum, natural history, and treatment","volume":"27","author":"Ovejero","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-024-01328-8","article-title":"Osteomalacia: A Challenging Diagnosis Adverse Event Associated with Intravenous Ferric Carboxymaltose-A Case Report","volume":"116","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","article-title":"High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment","volume":"45","author":"Boots","year":"2022","journal-title":"Drug Saf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1007\/s12011-021-02598-1","article-title":"The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: A Systematic Review and Time-Response Meta-Analysis","volume":"199","author":"Magzoub","year":"2021","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The International X-Linked Hypophosphatemia (XLH) Registry: First interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): Rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMc2405746","article-title":"Acquired Osteomalacia Associated with Autoantibodies against PHEX","volume":"392","author":"Hoshino","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-022-06516-6","article-title":"Long-term use of burosumab for the treatment of tumor-induced osteomalacia","volume":"34","author":"Crotti","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Brener, R., Zeitlin, L., Lebenthal, Y., and Brener, A. (2022). Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.947814"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e230242","DOI":"10.20945\/2359-4292-2023-0242","article-title":"Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review","volume":"68","author":"Dodamani","year":"2024","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00223-024-01250-z","article-title":"Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data","volume":"115","author":"Kiafzezi","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/clinem\/dgad440","article-title":"Efficacy and Safety of Burosumab in X-linked Hypophosphatemia","volume":"109","author":"Wang","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s13023-022-02590-5","article-title":"Growth hormone treatment improves final height in children with X-linked hypophosphatemia","volume":"17","author":"Zhukouskaya","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","article-title":"Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets","volume":"33","author":"Meyerhoff","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.1096\/fj.201802007R","article-title":"MAPK inhibition and growth hormone: A promising therapy in XLH","volume":"33","author":"Fuente","year":"2019","journal-title":"FASEB J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shin, M.H., Kim, J., Lim, S.A., Kim, J., and Lee, K.M. (2020). Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072531"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"eabj5018","DOI":"10.1126\/sciadv.abj5018","article-title":"A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia","volume":"7","author":"Zhukouskaya","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"436","DOI":"10.14740\/jocmr4820","article-title":"Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho\/Fibroblast Growth Factor 23 System","volume":"14","author":"Bittmann","year":"2022","journal-title":"J. Clin. Med. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jbmr.3878","article-title":"Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J. Bone Miner. Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:56Z","timestamp":1760035556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":82,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["biom15091321"],"URL":"https:\/\/doi.org\/10.3390\/biom15091321","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}